FSTL1 demonstrates potential as a valuable biomarker that can aid current diagnostic tools for OSA and help evaluate treatment efficacy; however, additional research is warranted to confirm its clinical applicability and explore its therapeutic potential. This evidence concerns the gene FSTL1 and obstructive sleep apnea syndrome.